SNDX Stock Price, Syndax Pharmaceuticals Quote, Chart

Market Summary

USD21.75-0.22

Delayed

-1.00%

SNDX Alerts

Big fall in earnings (Y/Y)

Losses in recent quarter

SNDX Stock Price

View Fullscreen

SNDX RSI Chart

SNDX Valuation

Market Cap

1.9B

Price/Earnings (Trailing)

-7.76

Price/Sales (Trailing)

13.61

Price/Free Cashflow

-9.11

SNDX Price/Sales (Trailing)

SNDX Profitability

Return on Equity

-48.92%

Return on Assets

-44.31%

Free Cashflow Yield

-10.97%

SNDX Fundamentals

SNDX Revenue

Revenue (TTM)

139.7M

SNDX Earnings

Earnings (TTM)

-240.6M

Earnings Growth (Yr)

-76.04%

Earnings Growth (Qtr)

0.1%

Breaking Down SNDX Revenue

52 Week Range

12.1423.55

(Low)(High)

Last 7 days

0.5%

Last 30 days

-4.4%

Last 90 days

-0.5%

Trailing 12 Months

7.9%

How does SNDX drawdown profile look like?

SNDX Financial Health

Current Ratio

8.93

SNDX Investor Care

Shares Dilution (1Y)

23.49%

Diluted EPS (TTM)

-3.24

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2021	1.5M	1.5M	13.5M	139.7M
2020	1.5M	1.5M	1.5M	1.5M
2019	1.5M	1.5M	1.5M	1.5M
2018	2.2M	2.3M	2.3M	1.5M
2017	1.2M	1.2M	1.2M	2.1M
2016	775.3K	923.5K	1.1M	1.2M
2015	0	0	0	627.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Syndax Pharmaceuticals Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Feb 07, 2024	meury william	acquired	-	-	17,000	-
Feb 07, 2024	goldan keith a.	acquired	-	-	46,700	chief financial officer
Feb 07, 2024	morrison briggs	acquired	-	-	17,000	-
Feb 07, 2024	huber martin h. jr.	acquired	-	-	17,000	-
Feb 07, 2024	jarrett jennifer	acquired	-	-	17,000	-
Feb 07, 2024	podlesak dennis	acquired	-	-	34,000	-
Feb 07, 2024	metzger michael a	acquired	-	-	146,250	chief executive officer
Feb 07, 2024	legault pierre	acquired	-	-	17,000	-
Feb 07, 2024	katkin keith	acquired	-	-	17,000	-
Feb 07, 2024	gallagher neil	acquired	-	-	47,813	president, head of r&d

Which funds bought or sold SNDX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 10, 2024	Clear Harbor Asset Management, LLC	new	-	213,153	213,153	0.02%
May 10, 2024	JPMORGAN CHASE & CO	reduced	-12.61	-633,254	16,242,600	-%
May 10, 2024	OSAIC HOLDINGS, INC.	added	57.06	27,031	64,070	-%
May 10, 2024	DIMENSIONAL FUND ADVISORS LP	reduced	-0.6	223,713	2,585,750	-%
May 10, 2024	WELLS FARGO & COMPANY/MN	added	27.43	199,600	694,318	-%
May 10, 2024	CREDIT SUISSE AG/	added	18.48	479,440	2,052,110	-%
May 10, 2024	PNC Financial Services Group, Inc.	reduced	-1.53	1,784	22,919	-%
May 10, 2024	BlackRock Inc.	added	7.65	28,141,900	179,748,000	-%
May 10, 2024	GROUP ONE TRADING, L.P.	reduced	-97.05	-540,179	18,159	-%
May 10, 2024	CITIGROUP INC	added	100	4,223,720	7,733,310	-%

Are Funds Buying or Selling SNDX?

Are funds buying SNDX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own SNDX

No. of Funds

Unveiling Syndax Pharmaceuticals Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	kynam capital management, lp	6.67%	5,660,000	SC 13G
Feb 14, 2024	point72 asset management, l.p.	3.3%	2,834,499	SC 13G/A
Feb 13, 2024	avidity partners management lp	4.7%	3,950,000	SC 13G/A
Feb 13, 2024	vanguard group inc	5.11%	4,335,353	SC 13G
Feb 08, 2024	wellington management group llp	8.94%	7,585,221	SC 13G/A
Jan 25, 2024	state street corp	5.91%	5,016,224	SC 13G/A
Jan 25, 2024	blackrock inc.	8.3%	7,015,548	SC 13G/A
Oct 31, 2023	point72 asset management, l.p.	4.5%	3,156,982	SC 13G
Oct 05, 2023	frazier life sciences public fund, l.p.	0.0%	0	SC 13G/A
Feb 14, 2023	nantahala capital management, llc	1.4%	975,705	SC 13G/A

Recent SEC filings of Syndax Pharmaceuticals Inc

View All Filings

Date Filed	Form Type	Document
May 08, 2024	10-Q	Quarterly Report
May 08, 2024	8-K	Current Report
Apr 02, 2024	ARS	ARS
Apr 02, 2024	DEF 14A	DEF 14A
Apr 02, 2024	DEFA14A	DEFA14A
Mar 18, 2024	8-K	Current Report
Feb 27, 2024	10-K	Annual Report
Feb 27, 2024	8-K	Current Report
Feb 27, 2024	S-3ASR	S-3ASR
Feb 27, 2024	S-8	Employee Benefits Plan

Peers (Alternatives to Syndax Pharmaceuticals Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	47.0B	6.8B	9.93%	-6.23%	-7.88	6.87	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	19.1B	2.0B	-2.86%	-28.22%	-57.66	9.56	75.20%	68.82%
BMRN	15.5B	2.5B	-8.14%	-14.08%	75.52	6.28	13.74%	186.89%
INCY	12.0B	3.8B	-3.24%	-16.29%	16.12	3.19	8.58%	129.81%
MID-CAP
BBIO	5.4B	107.9M	1.09%	107.81%	-9.83	48.09	54.84%	-28.31%
APLS	5.2B	524.1M	-22.77%	-53.41%	-12.37	9.85	394.93%	39.61%
AXSM	3.5B	251.0M	1.40%	-8.18%	-11.81	13.94	73.58%	-86.73%
ARWR	3.1B	240.7M	-5.68%	-38.85%	-6.52	12.77	-1.03%	-213.43%
ACAD	2.5B	813.8M	-16.31%	-29.84%	-1.5K	3.09	56.43%	98.83%
SMALL-CAP
CPRX	1.8B	411.3M	-0.76%	-10.51%	28.39	4.49	60.38%	-34.49%
NVAX	627.6M	996.6M	1.36%	-50.17%	-1.57	0.63	-26.66%	65.49%
CRBP	467.4M	881.7K	16.76%	369.92%	-13.85	481.06	-77.61%	33.36%
INO	261.3M	4.9M	-4.04%	14.81%	-1.93	53.69	-54.97%	51.71%
IBIO	6.6M	2.1M	-14.75%	74.53%	-0.24	2.14	-13.45%	66.37%

Syndax Pharmaceuticals Inc News

Latest updates

Syndax Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2018Q2	2018Q1	2017Q4	2017Q3	2017Q2	2017Q1	2016Q4
Revenue	922.8%	126,576	12,375	379	379	380	379	379	379	380	379	379	379	380	379	379	379	1,193	305	305	305	305
Operating Expenses	-4.9%	30,827	32,407	22,713	27,542	20,240	20,232	16,989	15,479	14,585	13,528	15,753	15,190	19,713	18,220	19,330	-	-	-	-	-	-
S&GA Expenses	1.8%	6,927	6,801	5,842	5,672	4,718	5,824	6,046	5,917	5,083	3,605	3,463	3,911	3,892	4,125	4,479	4,791	-	-	-	-	-
R&D Expenses	-6.7%	23,901	25,606	16,871	21,870	15,522	14,408	10,943	9,562	9,502	9,923	12,290	11,279	15,821	14,095	14,851	-	-	-	-	-	-
Interest Expenses	-101.1%	-7.00	649	634	623	635	635	638	449	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	566.1%	96,198	-20,639	-22,910	-27,723	-20,423	-20,437	-17,062	-15,236	-14,000	-12,829	-14,916	-14,302	-18,837	-17,338	-18,388	-	-	-	-	-	-
Net Income Margin	102.6%	0.18*	-6.79*	-60.31*	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Free Cashflow	503.5%	100,695	-24,958	-24,059	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-11.4%	543	613	399	431	460	497	360	406	422	450	240	263	280	301	179	193	105	64.00	76.00	87.00	99.00
Current Assets	-21.9%	454	581	381	409	442	490	358	392	420	448	238	263	279	299	177	192	104	62.00	75.00	86.00	98.00
Cash Equivalents	-61.2%	115	295	95.00	97.00	58.00	74.00	71.00	120	189	222	71.00	68.00	64.00	115	56.00	54.00	45.00	25.00	31.00	27.00	58.00
Net PPE	-37.5%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Liabilities	-12.9%	51.00	59.00	40.00	31.00	24.00	30.00	22.00	44.00	48.00	41.00	40.00	48.00	51.00	48.00	47.00	45.00	52.00	32.00	32.00	32.00	31.00
Current Liabilities	-12.5%	51.00	58.00	39.00	30.00	24.00	29.00	21.00	31.00	31.00	21.00	29.00	24.00	25.00	19.00	15.00	12.00	19.00	18.00	18.00	17.00	16.00
Shareholder's Equity	-11.2%	492	554	359	400	436	467	338	362	375	408	199	215	228	252	132	148	54.00	32.00	44.00	55.00	69.00
Retained Earnings	-8.0%	-974	-902	-829	-778	-734	-693	-653	-618	-580	-543	-639	-619	-596	-568	-548	-527	-510	-495	-481	-468	-453
Additional Paid-In Capital	0.8%	1,467	1,456	1,190	1,179	1,170	1,161	994	982	956	952	839	834	825	821	680	675	564	527	525	524	522
Shares Outstanding	0.2%	85.00	85.00	70.00	69.00	68.00	68.00	61.00	60.00	59.00	52.00	52.00	52.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	1,452,442	-	-	-	1,084	-	-	-	833	-	-	-	500	-	-	-	208	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-102.1%	-83,548	-41,349	-44,653	-35,371	-39,228	-22,894	-28,544	-40,306	-41,931	100,709	-24,944	-24,045	-22,589	-15,631	-18,297	-21,407	-15,925	-12,727	-8,529	-12,525	-16,831
Share Based Compensation	6.9%	8,899	8,327	8,321	8,065	6,238	4,241	4,362	3,938	3,478	3,929	3,381	3,240	2,767	2,035	3,063	2,130	1,829	1,525	1,550	1,338	1,592
Cashflow From Investing	-510.2%	-99,399	-16,290	40,077	73,907	19,915	-137,629	-6,793	-49,948	8,182	-59,956	26,631	21,680	-29,228	-64,140	19,275	-78,612	-19,053	6,596	12,364	-18,931	12,752
Cashflow From Financing	-99.2%	2,168	258,483	1,851	1,324	2,474	163,502	-13,525	21,720	557	109,779	1,705	6,020	960	138,658	1,767	109,001	54,998	58.00	80.00	6.00	28,426

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

SNDX Income Statement

2024-03-31

Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating expenses:
Research and development	$ 56,492	$ 34,054
Selling, general and administrative	23,022	11,961
Total operating expenses	79,514	46,015
Loss from operations	(79,514)	(46,015)
Other income (expense), net:
Interest expense	(55)	(40)
Interest income	7,256	5,076
Other expense	(87)	(147)
Total other income, net	7,114	4,889
Net loss	(72,400)	(41,126)
Other comprehensive loss:
Unrealized (loss) gain on short-term investments	(974)	470
Comprehensive loss	(73,374)	(40,656)
Net loss attributable to common stockholders	$ (72,400)	$ (41,126)
Net loss per share attributable to common stockholders—basic	$ (0.85)	$ (0.59)
Net loss per share attributable to common stockholders—diluted	$ (0.85)	$ (0.59)
Weighted-average number of common shares used to compute net loss per share attributable to common stockholders —basic	85,213,200	69,438,890
Weighted-average number of common shares used to compute net loss per share attributable to common stockholders—diluted	85,213,200	69,438,890

SNDX Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 114,615	$ 295,394
Short-term investments	319,963	275,304
Short-term deposits	8,583	6,885
Other receivable	6,073	0
Prepaid expenses and other current assets	4,665	3,293
Total current assets	453,899	580,876
Long-term investments	87,416	29,829
Property and equipment, net	5	8
Right-of-use asset, net	1,243	1,487
Restricted cash	217	217
Other assets	248	463
Total assets	543,028	612,880
Current liabilities:
Accounts payable	8,809	9,961
Collaboration payable, net	7,547	7,232
Accrued expenses and other current liabilities	33,395	39,856
Current portion of right-of-use liability	1,042	1,035
Current portion of capital lease	12	12
Total current liabilities	50,805	58,096
Long-term liabilities:
Right-of-use liability, less current portion	327	578
Capital lease, less current portion	7	10
Total long-term liabilities	334	588
Total liabilities	51,139	58,684
Commitments and contingencies (Note 12)
Stockholders’ equity:
Preferred stock, $0.001 par value, 10,000,000 shares authorized; 0 shares outstanding at March 31, 2024 and December 31, 2023	0	0
Common stock, $0.0001 par value, 200,000,000 shares authorized; 84,979,686 and 84,826,632 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	8	8
Additional paid-in capital	1,467,437	1,456,370
Accumulated other comprehensive (loss) gain	(756)	218
Accumulated deficit	(974,800)	(902,400)
Total stockholders’ equity	491,889	554,196
Total liabilities and stockholders’ equity	$ 543,028	$ 612,880

About Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 for the treatment of KMT2A rearranged (KMT2Ar) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.

CEO	Mr. Michael A. Metzger M.B.A.
WEBSITE	syndax.com
INDUSTRY	Biotechnology
EMPLOYEES	107

Syndax Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Syndax Pharmaceuticals Inc? What does SNDX stand for in stocks?

SNDX is the stock ticker symbol of Syndax Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Syndax Pharmaceuticals Inc (SNDX)?

As of Thu May 09 2024, market cap of Syndax Pharmaceuticals Inc is 1.87 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of SNDX stock?

You can check SNDX's fair value in chart for subscribers.

What is the fair value of SNDX stock?

You can check SNDX's fair value in chart for subscribers. The fair value of Syndax Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Syndax Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for SNDX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Syndax Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether SNDX is over valued or under valued. Whether Syndax Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Syndax Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SNDX.

What is Syndax Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu May 09 2024, SNDX's PE ratio (Price to Earnings) is -7.76 and Price to Sales (PS) ratio is 13.61. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SNDX PE ratio will change depending on the future growth rate expectations of investors.